InsiderClue
← All stocks

Indivior Pharmaceuticals, Inc.

INDV Net buying
CIK 0001625297 #1439 in the set updated 17 Sep 2026
Bought (120 mo)
$311.56K
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$2.83M
$2.83M on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 3 sales
Net
−$2.52M
+$311.56K against sales at will

By person

13 insiders · 13 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Heidbreder Christian
Chief Scientific Officer
—
$1.47M (2) scheduled
−$1.47M
209,337
0.1774%
$7.47M
+33.2%
Preblick Ryan
Chief Financial Officer
—
$1.36M (1) scheduled
−$1.36M
284,751
0.2413%
$10.16M
+1.5%
Anderson Woodrow D
Chief Accounting Officer
$107.96K (2)
—
+$107.96K
27,638
0.0234%
$986.40K
+529.6%
Wheadon David E.
Director
$62.68K (1)
—
+$62.68K
30,780
0.0261%
$1.10M
+143.8%
Kingsley Stuart A
Director
$29.95K (1)
—
+$29.95K
12,100
0.0103%
$431.85K
+1,215%
Ryan Barbara
Director
$28.69K (3)
—
+$28.69K
12,242
0.0104%
$436.92K
+930.5%
Humphreys Keith
Director
$27.43K (1)
—
+$27.43K
16,042
0.0136%
$572.54K
+219.1%
NINIVAGGI DANIEL A
Director
$27.43K (1)
—
+$27.43K
27,163
0.0230%
$969.45K
+68.2%
Stejbach Mark
Director
$27.43K (1)
—
+$27.43K
27,087
0.0230%
$966.74K
+68.5%
Ciaffoni Joseph
Chief Executive Officer
—
—
—
790,330
0.6697%
$28.21M
+1,311%
Burris Jeffrey W
Chief Legal Officer
—
—
—
71,518
0.0606%
$2.55M
+9,310%
Barry Patrick A
Chief Commercial Officer
—
—
—
31,380
0.0266%
$1.12M
—
Thompson Juliet
Director
—
—
—
12,973
0.0110%
$463.01K
+237.0%

Individual transactions

3
Insider
Date
Role
Action
Shares
Price
Amount
Heidbreder Christian
10 Jul 2026
Chief Scientific Officer
Sold on a plan
18,586
$41.14
$764.63K
Heidbreder Christian
11 Jun 2026
Chief Scientific Officer
Sold on a plan
18,586
$38.06
$707.38K
Preblick Ryan
8 Jun 2026
Chief Financial Officer
Sold on a plan
36,000
$37.70
$1.36M
Show all 13 transactions →

What was left out

Form 4 filings counted 39
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 2,656,762
History held since 7 Jan 2026